[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-001", "question": "A 26-year-old G2P1 at 30 weeks' gestation presents with new-onset severe occipital headache, visual scotomata, and right upper quadrant pain. BP is 168/108 mmHg, HR 88, reflexes 3+ with 1-2 beats of clonus. Fetal heart tracing is category I. Labs: platelets 86,000/µL, AST 145 U/L, ALT 162 U/L, creatinine 0.9 mg/dL, urine protein/creatinine ratio 0.5. She received 10 mg IV hydralazine in triage 20 minutes ago; current BP is 162/104 mmHg. She desires future fertility and vaginal delivery if safe. What is the most appropriate NEXT step in management?", "options": ["Administer IV labetalol now and plan for induction of labor at 34 weeks", "Initiate magnesium sulfate and proceed with immediate induction of labor", "Initiate magnesium sulfate and administer betamethasone; plan delivery within 24 hours", "Administer additional IV hydralazine and observe; defer delivery until 34 weeks if blood pressure controlled", "Start oral labetalol and discharge with close outpatient follow-up and twice-weekly NSTs"], "answer": "C", "answer_index": 2, "explanation": "She has preeclampsia with severe features and evolving HELLP (thrombocytopenia, RUQ pain, transaminitis) at 30 weeks. For severe features <34 weeks, optimal care is magnesium, corticosteroids, and expedited delivery within 24 hours at a tertiary center, not expectant management. Immediate induction ignores steroid window and maternal stability; outpatient or prolonged expectant management is unsafe given platelets <100,000 and worsening symptoms.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 30 weeks’ gestation; BP ≥160/110 despite IV hydralazine; severe headache, visual symptoms, RUQ pain; hyperreflexia with clonus; platelets 86,000/µL; elevated AST/ALT; proteinuric hypertension. These meet criteria for preeclampsia with severe features and evolving HELLP. At <34 weeks with severe features and thrombocytopenia plus symptoms, standard management is maternal stabilization with magnesium sulfate for seizure prophylaxis, corticosteroids for fetal lung maturity, and planned delivery soon (typically within 24 hours) rather than prolonged expectant management.\\nOption C correctly bundles magnesium, betamethasone, and expedited (but not necessarily immediate) delivery, matching ACOG-style guidance. A and D inappropriately defer delivery to 34 weeks despite severe features and platelets <100,000. B omits steroids and pushes immediate induction without using the steroid window. E is dangerously inappropriate outpatient management in a clearly unstable patient.\\nNo major medical inaccuracies are present; wording “within 24 hours” is broadly consistent with recommendations for urgent delivery once stabilized.\\nMinimal fix: Explicitly state “transfer to/management at tertiary care center with initiation of magnesium sulfate, betamethasone, and planned delivery within 24 hours.”\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 30 weeks’ gestation; BP ≥160/110 despite IV hydralazine; severe headache, visual symptoms, RUQ pain; hyperreflexia with clonus; platelets 86,000/µL; elevated AST/ALT; proteinuric hypertension. These meet criteria for preeclampsia with severe features and evolving HELLP. At <34 weeks with severe features and thrombocytopenia plus symptoms, standard management is maternal stabilization with magnesium sulfate for seizure prophylaxis, corticosteroids for fetal lung maturity, and planned delivery soon (typically within 24 hours) rather than prolonged expectant management.\nOption C correctly bundles magnesium, betamethasone, and expedited (but not necessarily immediate) delivery, matching ACOG-style guidance. A and D inappropriately defer delivery to 34 weeks despite severe features and platelets <100,000. B omits steroids and pushes immediate induction without using the steroid window. E is dangerously inappropriate outpatient management in a clearly unstable patient.\nNo major medical inaccuracies are present; wording “within 24 hours” is broadly consistent with recommendations for urgent delivery once stabilized.\nMinimal fix: Explicitly state “transfer to/management at tertiary care center with initiation of magnesium sulfate, betamethasone, and planned delivery within 24 hours.”", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-002", "question": "A 58-year-old man with ischemic cardiomyopathy (LVEF 20%), CRT-D in place, and NYHA class III symptoms despite optimal GDMT (sacubitril/valsartan, carvedilol, spironolactone, empagliflozin, loop diuretic) presents with weight gain and dyspnea. BP 104/66 mmHg, HR 72 (biventricular paced), JVP 12 cm, bibasilar crackles, moderate ascites, no peripheral edema. Labs: Na 130 mEq/L, K 4.4, creatinine 1.8 (baseline 1.3), NT-proBNP 12,000 pg/mL. Echo: LVEF 20%, severe functional MR, normal RV size, mildly reduced RV function, PASP 55 mmHg. Right heart cath: RAP 18 mmHg, PCWP 32 mmHg, CI 1.7 L/min/m², SVR 2100 dyn·s/cm⁵. After IV diuresis, he remains hypotensive with CI 1.6. He is INTERMACS profile 4. What is the best definitive next step?", "options": ["Add continuous IV milrinone as palliative inotropic therapy without advanced therapies", "Refer for urgent isolated cardiac transplantation listing status 2 without LVAD bridge", "Evaluate for transcatheter edge-to-edge repair (TEER) of the mitral valve to reduce MR", "Refer for durable LVAD implantation as bridge to transplant or destination therapy", "Implant a percutaneous Impella device as bridge to decision in the ICU"], "answer": "D", "answer_index": 3, "explanation": "He has advanced, stage D HFrEF with persistent low-output symptoms, high filling pressures, and INTERMACS profile 4, making him appropriate for durable LVAD as bridge to transplant or destination. Isolated transplant without LVAD is not ideal given instability; TEER is for less advanced, stable patients. Chronic inotropes or short-term MCS alone are not definitive strategies in a transplant/LVAD candidate.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: Severe ischemic HFrEF with LVEF 20%; NYHA III despite maximally titrated guideline-directed medical therapy and CRT-D; evidence of chronic congestion and low output (JVP 12 cm, crackles, ascites, Na 130, rising creatinine, NT‑proBNP 12,000); invasive hemodynamics showing markedly elevated RAP/PCWP, low CI 1.7 → 1.6 L/min/m² with high SVR; INTERMACS profile 4 (resting symptoms, recurrent congestion despite therapy); persistent hypotension/low CI after IV diuresis.\\n\\nThese collectively indicate advanced, stage D HFrEF appropriate for durable mechanical circulatory support. Choice D (durable LVAD as bridge to transplant or destination therapy) is the guideline-concordant definitive strategy for an INTERMACS 3–4 ambulatory but declining patient.\\n\\nOther options: A (palliative inotrope without advanced therapies) is not “best definitive” in an LVAD/transplant candidate; B (urgent isolated transplant) is less appropriate than LVAD bridge given instability and typical organ scarcity; C (TEER) is usually for less advanced, hemodynamically stable patients and would not address global low output; E (Impella) is short-term MCS for acute cardiogenic shock (INTERMACS 1–2), not profile 4 chronic failure.\\n\\nMinimal fix: Specify he has acceptable LVAD/transplant candidacy (no prohibitive comorbidities) to fully justify LVAD referral as best definitive step.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: Severe ischemic HFrEF with LVEF 20%; NYHA III despite maximally titrated guideline-directed medical therapy and CRT-D; evidence of chronic congestion and low output (JVP 12 cm, crackles, ascites, Na 130, rising creatinine, NT‑proBNP 12,000); invasive hemodynamics showing markedly elevated RAP/PCWP, low CI 1.7 → 1.6 L/min/m² with high SVR; INTERMACS profile 4 (resting symptoms, recurrent congestion despite therapy); persistent hypotension/low CI after IV diuresis.\n\nThese collectively indicate advanced, stage D HFrEF appropriate for durable mechanical circulatory support. Choice D (durable LVAD as bridge to transplant or destination therapy) is the guideline-concordant definitive strategy for an INTERMACS 3–4 ambulatory but declining patient.\n\nOther options: A (palliative inotrope without advanced therapies) is not “best definitive” in an LVAD/transplant candidate; B (urgent isolated transplant) is less appropriate than LVAD bridge given instability and typical organ scarcity; C (TEER) is usually for less advanced, hemodynamically stable patients and would not address global low output; E (Impella) is short-term MCS for acute cardiogenic shock (INTERMACS 1–2), not profile 4 chronic failure.\n\nMinimal fix: Specify he has acceptable LVAD/transplant candidacy (no prohibitive comorbidities) to fully justify LVAD referral as best definitive step.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-003", "question": "A previously healthy 4-year-old boy presents with 10 days of fever to 39.5°C, conjunctival injection without exudate, cracked lips, polymorphous trunk rash, edema and erythema of hands and feet, and cervical lymphadenopathy. Symptoms partially improved after ibuprofen but recur when stopped. Day-10 echocardiogram: diffuse coronary artery ectasia with z-scores 2.3-2.7, mild LV dysfunction (EF 50%), and small pericardial effusion. Labs: WBC 14,000/µL, platelets 520,000/µL, CRP 10 mg/dL, ESR 80 mm/hr, ALT mildly elevated, sterile pyuria. COVID serology and respiratory viral panel are negative. He has not yet received IVIG. What is the most appropriate initial treatment strategy now?", "options": ["Single dose IVIG 2 g/kg plus high-dose aspirin only", "IVIG 2 g/kg, high-dose aspirin, and a single dose of IV methylprednisolone 30 mg/kg", "IVIG 2 g/kg, low-dose aspirin, and infliximab 5 mg/kg", "IVIG 2 g/kg, high-dose aspirin, and anakinra 2 mg/kg/day", "High-dose aspirin alone because presentation is after day 10 of illness"], "answer": "B", "answer_index": 1, "explanation": "He has classic Kawasaki disease with coronary changes and delayed presentation, which confers high risk of IVIG resistance and coronary progression. Current risk-adapted approaches favor adjunctive corticosteroids with IVIG in high-risk patients (coronary involvement and very elevated inflammatory markers), even after day 10. Aspirin monotherapy is inadequate; biologics are reserved for IVIG-resistant disease.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: 4-year-old boy with ≥10 days of high fever; classic 4/5 Kawasaki principal features (bilateral nonexudative conjunctivitis, oral changes, polymorphous rash, extremity changes, cervical lymphadenopathy); labs with thrombocytosis, elevated CRP/ESR, mild transaminitis, sterile pyuria; echocardiogram already showing diffuse coronary ectasia (z-scores 2.3–2.7), mild LV dysfunction, small pericardial effusion; has not yet received IVIG; symptoms persist when NSAID stopped.\\n\\nThese findings meet complete Kawasaki disease with early coronary involvement and high inflammatory burden, which current AHA/JP guidelines consider high-risk for IVIG resistance and progression. Best initial therapy is IVIG 2 g/kg plus high-dose aspirin with adjunctive corticosteroids. Choice B matches this.\\n\\nWhy others are worse: A omits steroids despite high-risk features. C uses low-dose (antiplatelet) aspirin and upfront infliximab, which is typically second-line for IVIG-resistant disease. D similarly uses anakinra (third-line/IVIG-resistant), not first-line. E contradicts guidelines: IVIG is still indicated after day 10 in ongoing inflammation and coronary changes.\\n\\nMinimal fix: Clarify in stem that management should follow current AHA Kawasaki guidelines, to anchor expectations and avoid regional practice variability concerns.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: 4-year-old boy with ≥10 days of high fever; classic 4/5 Kawasaki principal features (bilateral nonexudative conjunctivitis, oral changes, polymorphous rash, extremity changes, cervical lymphadenopathy); labs with thrombocytosis, elevated CRP/ESR, mild transaminitis, sterile pyuria; echocardiogram already showing diffuse coronary ectasia (z-scores 2.3–2.7), mild LV dysfunction, small pericardial effusion; has not yet received IVIG; symptoms persist when NSAID stopped.\n\nThese findings meet complete Kawasaki disease with early coronary involvement and high inflammatory burden, which current AHA/JP guidelines consider high-risk for IVIG resistance and progression. Best initial therapy is IVIG 2 g/kg plus high-dose aspirin with adjunctive corticosteroids. Choice B matches this.\n\nWhy others are worse: A omits steroids despite high-risk features. C uses low-dose (antiplatelet) aspirin and upfront infliximab, which is typically second-line for IVIG-resistant disease. D similarly uses anakinra (third-line/IVIG-resistant), not first-line. E contradicts guidelines: IVIG is still indicated after day 10 in ongoing inflammation and coronary changes.\n\nMinimal fix: Clarify in stem that management should follow current AHA Kawasaki guidelines, to anchor expectations and avoid regional practice variability concerns.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-004", "question": "A 32-year-old woman with mixed connective tissue disease (U1-RNP positive) on mycophenolate mofetil and low-dose prednisone presents with 3 months of progressive exertional dyspnea and near-syncope. Exam: loud P2, right ventricular heave, no crackles, no edema. HR 94, BP 108/68 mmHg, O2 sat 95% on room air. CT chest: no interstitial lung disease, no PE. TTE: normal LV, moderately dilated RV with reduced function, estimated PASP 75 mmHg, no shunt. Right heart cath: mPAP 46 mmHg, PAOP 9 mmHg, CI 2.0 L/min/m², PVR 9 Wood units. Autoantibodies: strong anti-U1-RNP, negative anti-Scl-70. She desires pregnancy within 1-2 years. What is the most appropriate initial advanced therapy strategy for her pulmonary hypertension?", "options": ["Start amlodipine after acute vasoreactivity testing, then titrate based on BP", "Initiate dual oral therapy with ambrisentan and tadalafil", "Initiate triple therapy including IV epoprostenol plus an endothelin receptor antagonist and a PDE-5 inhibitor", "Start inhaled treprostinil monotherapy and observe functional response", "Use riociguat monotherapy given connective tissue disease-associated PAH"], "answer": "C", "answer_index": 2, "explanation": "She has high-risk WHO group 1 CTD-associated PAH (RV dysfunction, mPAP 46, CI 2.0, PVR 9) and plans pregnancy (a major risk), warranting aggressive up-front therapy. Modern guidelines recommend initial triple therapy with parenteral prostacyclin in high-risk PAH patients. CCBs are only for acute vasoreactivity responders; dual or single oral agents are insufficient for this profile.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Young woman with mixed connective tissue disease; hemodynamics consistent with WHO Group 1 PAH (mPAP 46, PAOP 9, PVR 9); evidence of RV dilation and dysfunction, high PASP, CI 2.0 L/min/m² → high-risk PAH. No ILD or left-heart disease. Desires pregnancy within 1–2 years, which is a major additional risk factor. Current ESC/ERS and related guidelines recommend initial combination therapy including parenteral prostacyclin for high‑risk PAH, especially CTD-associated.\\nChoice C (initial triple therapy with IV epoprostenol plus ERA + PDE-5 inhibitor) matches guideline-based first-line strategy for high-risk Group 1 PAH. A is inappropriate: CCBs only for acute vasoreactivity responders, and vasoreactivity not yet shown or likely in CTD-PAH. B and E (dual or single oral therapy) are typically reserved for low–intermediate risk; insufficient for high-risk profile. D (inhaled treprostinil monotherapy) is underpowered for high-risk disease and not standard initial therapy.\\nNo major logical or medical inaccuracies noted.\\nMinimal fix: Explicitly state her WHO functional class (e.g., III–IV) to more clearly justify the “high-risk” designation and triple-therapy indication.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Young woman with mixed connective tissue disease; hemodynamics consistent with WHO Group 1 PAH (mPAP 46, PAOP 9, PVR 9); evidence of RV dilation and dysfunction, high PASP, CI 2.0 L/min/m² → high-risk PAH. No ILD or left-heart disease. Desires pregnancy within 1–2 years, which is a major additional risk factor. Current ESC/ERS and related guidelines recommend initial combination therapy including parenteral prostacyclin for high‑risk PAH, especially CTD-associated.\nChoice C (initial triple therapy with IV epoprostenol plus ERA + PDE-5 inhibitor) matches guideline-based first-line strategy for high-risk Group 1 PAH. A is inappropriate: CCBs only for acute vasoreactivity responders, and vasoreactivity not yet shown or likely in CTD-PAH. B and E (dual or single oral therapy) are typically reserved for low–intermediate risk; insufficient for high-risk profile. D (inhaled treprostinil monotherapy) is underpowered for high-risk disease and not standard initial therapy.\nNo major logical or medical inaccuracies noted.\nMinimal fix: Explicitly state her WHO functional class (e.g., III–IV) to more clearly justify the “high-risk” designation and triple-therapy indication.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-005", "question": "A 24-year-old primigravida at 11 weeks presents with severe nausea, non-bloody emesis 10-15 times daily, 4-kg weight loss, orthostatic tachycardia, and inability to keep down oral medications despite pyridoxine/doxylamine and rectal promethazine. She has ketonuria, Na 131 mEq/L, K 2.9 mEq/L, bicarbonate 19 mEq/L, ALT 78 U/L, AST 65 U/L, normal lipase and thyroid function. Ultrasound: single viable intrauterine pregnancy. She requests to avoid hospitalization if possible and is anxious about teratogenic risk. What is the most appropriate next-step pharmacologic management in addition to IV fluids and electrolyte repletion?", "options": ["Start oral ondansetron and allow discharge with close outpatient follow-up", "Begin continuous subcutaneous metoclopramide infusion as an outpatient", "Administer IV ondansetron and admit for parenteral nutrition via PICC line", "Start transdermal scopolamine and oral mirtazapine", "Administer IV chlorpromazine now and transition to scheduled IV ondansetron or metoclopramide in the hospital"], "answer": "E", "answer_index": 4, "explanation": "She has hyperemesis gravidarum with significant volume depletion and electrolyte derangements, requiring inpatient care and parenteral antiemetics. Phenothiazines (e.g., IV chlorpromazine) followed by scheduled IV ondansetron or metoclopramide are evidence-based for refractory hyperemesis. Outpatient oral or SC regimens are inappropriate given inability to tolerate PO; TPN is reserved for failure of intensive antiemetic therapy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 11-week primigravida with severe, refractory vomiting (10–15x/day), 4-kg weight loss, orthostatic tachycardia, ketonuria, hyponatremia, significant hypokalemia, mild metabolic acidosis, mild transaminitis, failure of first-line therapy (pyridoxine/doxylamine, rectal promethazine), and inability to keep down oral meds, plus patient request to avoid admission. These findings define hyperemesis gravidarum with significant volume/electrolyte derangement and functional inability to use enteral meds, indicating need for inpatient IV therapy.\\nOption E appropriately provides immediate IV phenothiazine and plans scheduled parenteral ondansetron or metoclopramide in the hospital, matching guideline-based escalation for refractory hyperemesis and acknowledging necessity of admission.\\nWhy others are worse: A uses oral route despite inability to keep PO and underestimates severity. B (outpatient SC) also avoids needed admission and repletion. C jumps prematurely to parenteral nutrition via PICC, reserved for failure of maximal antiemetics. D (scopolamine, mirtazapine) is not standard first parenteral escalation in this setting and still relies partly on oral route.\\nMain medical issue: Minor—specific choice of phenothiazine agent/dosing not detailed, but class is appropriate.\\nMinimal fix: Explicitly state “She is unable to tolerate any oral intake including pills” to further justify parenteral-only approach and admission over oral/SC outpatient options.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 11-week primigravida with severe, refractory vomiting (10–15x/day), 4-kg weight loss, orthostatic tachycardia, ketonuria, hyponatremia, significant hypokalemia, mild metabolic acidosis, mild transaminitis, failure of first-line therapy (pyridoxine/doxylamine, rectal promethazine), and inability to keep down oral meds, plus patient request to avoid admission. These findings define hyperemesis gravidarum with significant volume/electrolyte derangement and functional inability to use enteral meds, indicating need for inpatient IV therapy.\nOption E appropriately provides immediate IV phenothiazine and plans scheduled parenteral ondansetron or metoclopramide in the hospital, matching guideline-based escalation for refractory hyperemesis and acknowledging necessity of admission.\nWhy others are worse: A uses oral route despite inability to keep PO and underestimates severity. B (outpatient SC) also avoids needed admission and repletion. C jumps prematurely to parenteral nutrition via PICC, reserved for failure of maximal antiemetics. D (scopolamine, mirtazapine) is not standard first parenteral escalation in this setting and still relies partly on oral route.\nMain medical issue: Minor—specific choice of phenothiazine agent/dosing not detailed, but class is appropriate.\nMinimal fix: Explicitly state “She is unable to tolerate any oral intake including pills” to further justify parenteral-only approach and admission over oral/SC outpatient options.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-006", "question": "A 17-year-old previously healthy boy is admitted to the ICU with septic shock due to meningococcemia, requiring norepinephrine and mechanical ventilation. On day 4, BP stabilizes and pressors are stopped. Over the next 24 hours, he develops rapidly worsening hypoxemia with PaO2/FiO2 ratio 90, diffuse bilateral infiltrates, and new hemoptysis. Hb drops from 11 to 8 g/dL without obvious bleeding. Platelets are 220,000/µL, PT/INR normal, PTT normal, fibrinogen 400 mg/dL. Urinalysis: 3+ blood, 2+ protein, many dysmorphic RBCs. Creatinine rises from 0.8 to 2.1 mg/dL. ANA negative, ANCA panel negative, complements normal. Bronchoscopy shows diffuse alveolar hemorrhage; cultures pending. What is the most appropriate next step in management?", "options": ["High-dose IV methylprednisolone and IV cyclophosphamide for presumed ANCA-negative pulmonary-renal vasculitis", "Plasmapheresis plus pulse steroids for suspected anti-GBM disease despite negative serology", "Supportive care only, assuming septic coagulopathy-related lung injury", "Kidney biopsy as soon as feasible to guide immunosuppression decisions", "Start rituximab and prednisone for suspected immune-complex GN related to sepsis"], "answer": "D", "answer_index": 3, "explanation": "He has a pulmonary-renal syndrome with DAH and GN but negative ANCA/anti-GBM serologies and preserved platelets/coagulation, making pure septic DIC unlikely. In this critically ill patient, tissue diagnosis is essential before committing to aggressive immunosuppression, especially with negative serologies. Early kidney biopsy best clarifies the etiology; empiric cytotoxic therapy or plasmapheresis without diagnosis carries high risk and may be inappropriate if the lesion is infection-related.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Teen with recent meningococcemia, now new pulmonary-renal syndrome: diffuse alveolar hemorrhage (DAH), hemoptysis, falling hemoglobin without external bleeding, active urinary sediment with dysmorphic RBCs/proteinuria, rising creatinine. Platelets and coagulation profile normal, fibrinogen normal ⇒ DIC/septic coagulopathy unlikely. ANCA, anti-GBM, ANA negative; complements normal. No clear serologic diagnosis for immune-mediated vasculitis or anti-GBM disease.\\nThese features strongly suggest a pulmonary-renal process requiring histologic clarification before high-risk immunosuppression, particularly in the context of recent severe infection. Thus, kidney biopsy as soon as safely feasible (D) is the most appropriate next step.\\nWhy other options are worse: A/B/E initiate aggressive immunosuppression (cyclophosphamide, plasmapheresis, rituximab) without a tissue diagnosis and with negative serologies; this is risky in a recently septic ICU patient. C ignores clear GN/DAH findings inconsistent with simple septic lung injury or coagulopathy.\\nMain medical accuracy issues: None; the logic and management priority (biopsy before cytotoxic therapy) align with standard practice for seronegative pulmonary-renal syndrome.\\nMinimal fix: Explicitly state anti-GBM antibody negative in the stem (rather than only “ANCA panel negative”) to fully support rejecting option B without inference.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Teen with recent meningococcemia, now new pulmonary-renal syndrome: diffuse alveolar hemorrhage (DAH), hemoptysis, falling hemoglobin without external bleeding, active urinary sediment with dysmorphic RBCs/proteinuria, rising creatinine. Platelets and coagulation profile normal, fibrinogen normal ⇒ DIC/septic coagulopathy unlikely. ANCA, anti-GBM, ANA negative; complements normal. No clear serologic diagnosis for immune-mediated vasculitis or anti-GBM disease.\nThese features strongly suggest a pulmonary-renal process requiring histologic clarification before high-risk immunosuppression, particularly in the context of recent severe infection. Thus, kidney biopsy as soon as safely feasible (D) is the most appropriate next step.\nWhy other options are worse: A/B/E initiate aggressive immunosuppression (cyclophosphamide, plasmapheresis, rituximab) without a tissue diagnosis and with negative serologies; this is risky in a recently septic ICU patient. C ignores clear GN/DAH findings inconsistent with simple septic lung injury or coagulopathy.\nMain medical accuracy issues: None; the logic and management priority (biopsy before cytotoxic therapy) align with standard practice for seronegative pulmonary-renal syndrome.\nMinimal fix: Explicitly state anti-GBM antibody negative in the stem (rather than only “ANCA panel negative”) to fully support rejecting option B without inference.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-007", "question": "A 6-week-old full-term girl presents with poor feeding, tachypnea, and sweating with feeds. Weight is at the 3rd percentile (previously 40th). Vitals: HR 180, RR 60, BP 70/40 mmHg in all extremities, O2 sat 96% RA. Exam: hepatomegaly, gallop rhythm, 2/6 holosystolic murmur at apex radiating to axilla, no differential pulses. CXR: cardiomegaly, pulmonary overcirculation. Echo: dilated LV with EF 20%, moderate MR, normal coronaries, no coarctation or structural shunt, normal RV function. ECG: sinus tachycardia. Blood and viral studies pending. After starting IV milrinone and diuretics, she stabilizes. What is the MOST appropriate next step in definitive management planning?", "options": ["Discontinue inotropes as soon as EF improves above 35% and transition to oral heart failure therapy only", "Urgently list for heart transplant as status 1A given high mortality of infantile dilated cardiomyopathy", "Begin high-dose IVIG for presumed viral myocarditis and defer consideration of mechanical support", "Evaluate for durable LVAD candidacy as bridge to transplant or recovery", "Schedule elective mitral valve repair to reduce regurgitation and improve LV function"], "answer": "D", "answer_index": 3, "explanation": "She has severe idiopathic/viral dilated cardiomyopathy with EF 20% and inotrope dependence, placing her at high risk of deterioration. Early evaluation for durable LVAD as bridge to transplant or recovery is recommended in infants with advanced heart failure who respond incompletely to medical therapy. Immediate transplant listing without MCS may be risky given wait times; valve surgery will not address primary LV dysfunction; IVIG alone is insufficient as definitive strategy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 6-week-old, full-term infant with new-onset severe dilated LV (EF 20%), symptoms of advanced heart failure (poor feeding, tachypnea, diaphoresis), growth faltering, cardiomegaly with pulmonary overcirculation, moderate MR secondary to LV dilation, normal coronaries and no structural CHD, currently stabilized but inotrope-dependent on IV milrinone. These findings indicate advanced systolic heart failure from idiopathic/viral dilated cardiomyopathy with high risk of decompensation, where early consideration of durable mechanical circulatory support as bridge-to-transplant or recovery is standard of care.\\nChoice D fits best: evaluation for durable LVAD candidacy aligns with pediatric heart failure/transplant practice for inotrope-dependent infants. A is inappropriate because weaning off inotropes without planning for MCS/transplant underestimates risk. B (urgent status 1A listing) skips key step of MCS planning given wait-time risk. C overemphasizes IVIG, which is not definitive management. E focuses on secondary MR, not primary LV failure. No major logical or medical inaccuracies.\\nMinimal fix: Clarify in stem that she remains inotrope-dependent after initial stabilization (eg, \\\"requires continuous milrinone to maintain perfusion\\\") to reinforce the advanced HF status prompting LVAD evaluation.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 6-week-old, full-term infant with new-onset severe dilated LV (EF 20%), symptoms of advanced heart failure (poor feeding, tachypnea, diaphoresis), growth faltering, cardiomegaly with pulmonary overcirculation, moderate MR secondary to LV dilation, normal coronaries and no structural CHD, currently stabilized but inotrope-dependent on IV milrinone. These findings indicate advanced systolic heart failure from idiopathic/viral dilated cardiomyopathy with high risk of decompensation, where early consideration of durable mechanical circulatory support as bridge-to-transplant or recovery is standard of care.\nChoice D fits best: evaluation for durable LVAD candidacy aligns with pediatric heart failure/transplant practice for inotrope-dependent infants. A is inappropriate because weaning off inotropes without planning for MCS/transplant underestimates risk. B (urgent status 1A listing) skips key step of MCS planning given wait-time risk. C overemphasizes IVIG, which is not definitive management. E focuses on secondary MR, not primary LV failure. No major logical or medical inaccuracies.\nMinimal fix: Clarify in stem that she remains inotrope-dependent after initial stabilization (eg, \"requires continuous milrinone to maintain perfusion\") to reinforce the advanced HF status prompting LVAD evaluation.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-008", "question": "A 29-year-old woman at 36+1 weeks with known SLE (class IV lupus nephritis in remission on azathioprine and hydroxychloroquine) presents with 3 days of severe frontal headache, visual blurring, and increasing lower extremity edema. BP 164/102 mmHg (baseline 110/70), HR 92. Labs: platelets 185,000/µL, AST 40 U/L, ALT 35 U/L, creatinine 1.3 mg/dL (baseline 1.1), urine protein/creatinine ratio 2.2 (baseline 1.8), C3 and C4 low, anti-dsDNA titer increased from 1:80 to 1:320, urinalysis with active sediment (RBC casts). Fetus is cephalic, reassuring NST. What is the most appropriate management strategy?", "options": ["Diagnose superimposed preeclampsia with severe features and proceed to immediate delivery", "Increase azathioprine dose and schedule induction at 39 weeks if no further worsening", "Administer IV methylprednisolone for suspected lupus nephritis flare and continue pregnancy with close monitoring", "Start magnesium sulfate and attempt blood pressure control; delay delivery until 37 weeks", "Add IV cyclophosphamide for nephritis flare and plan delivery after disease control"], "answer": "C", "answer_index": 2, "explanation": "She has overlapping features but labs favor SLE flare: rising dsDNA, low complement, active urinary sediment with only mild new proteinuria and preserved platelets/LFTs. At 36 weeks, severe preeclampsia would typically show worsening proteinuria and other end-organ features. Pulse steroids for lupus nephritis flare while continuing pregnancy with close monitoring is appropriate; immediate delivery is not mandatory unless maternal or fetal status deteriorates.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: 36+1 weeks with prior class IV lupus nephritis; new severe headache and visual blurring; new hypertension 164/102 from 110/70; platelets and LFTs normal; creatinine only slightly ↑ from 1.1 to 1.3; protein/Cr only mildly increased (1.8→2.2); low complement, markedly rising anti-dsDNA, and active urine sediment (RBC casts). These serologies and urinary findings strongly favor an SLE nephritis flare over superimposed preeclampsia, which more typically features rising proteinuria and may show thrombocytopenia, elevated LFTs, and no active sediment.\\n\\nChoice C (IV methylprednisolone for lupus flare with close monitoring) matches standard management of suspected active nephritis in late pregnancy when maternal/fetal status is stable. A (immediate delivery) overcalls preeclampsia; diagnostic data favor flare. B under-treats a flare and delays therapy. D treats as preeclampsia without addressing autoimmune activity. E cyclophosphamide is generally avoided in late pregnancy and not first-line acutely here.\\n\\nMain medical issue: symptoms (headache/visual) could be from either process, but labs appropriately drive toward flare.\\n\\nMinimal fix: Explicitly note no other severe preeclampsia features (e.g., normal LFTs, platelets, no pulmonary edema) to further clarify reasoning, though item is already defensible.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: 36+1 weeks with prior class IV lupus nephritis; new severe headache and visual blurring; new hypertension 164/102 from 110/70; platelets and LFTs normal; creatinine only slightly ↑ from 1.1 to 1.3; protein/Cr only mildly increased (1.8→2.2); low complement, markedly rising anti-dsDNA, and active urine sediment (RBC casts). These serologies and urinary findings strongly favor an SLE nephritis flare over superimposed preeclampsia, which more typically features rising proteinuria and may show thrombocytopenia, elevated LFTs, and no active sediment.\n\nChoice C (IV methylprednisolone for lupus flare with close monitoring) matches standard management of suspected active nephritis in late pregnancy when maternal/fetal status is stable. A (immediate delivery) overcalls preeclampsia; diagnostic data favor flare. B under-treats a flare and delays therapy. D treats as preeclampsia without addressing autoimmune activity. E cyclophosphamide is generally avoided in late pregnancy and not first-line acutely here.\n\nMain medical issue: symptoms (headache/visual) could be from either process, but labs appropriately drive toward flare.\n\nMinimal fix: Explicitly note no other severe preeclampsia features (e.g., normal LFTs, platelets, no pulmonary edema) to further clarify reasoning, though item is already defensible.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-009", "question": "An intubated 65-year-old woman with severe influenza A pneumonia develops refractory hypoxemia despite lung-protective ventilation (TV 6 mL/kg, PEEP 14 cm H2O, FiO2 0.9) and paralysis. PaO2/FiO2 ratio is 70. She is placed on prone positioning for 16 hours/day with transient improvement but remains PaO2/FiO2 <80. Hemodynamics: MAP 72 mmHg on low-dose norepinephrine, lactate 1.8 mmol/L. No significant comorbidities; BMI 30 kg/m². Family consents to aggressive support. The center has on-site ECMO with experienced team but limited capacity. Which of the following is the most appropriate next step?", "options": ["Increase PEEP to 20 cm H2O and accept permissive hypercapnia before considering ECMO", "Initiate venovenous ECMO now due to refractory severe ARDS despite optimal conventional therapy", "Switch to high-frequency oscillatory ventilation for rescue oxygenation", "Trial inhaled nitric oxide and further proning cycles before deciding on ECMO", "Initiate venoarterial ECMO because of concurrent vasopressor use"], "answer": "B", "answer_index": 1, "explanation": "She has severe ARDS with PaO2/FiO2 <80 despite optimal lung-protective ventilation, high PEEP, paralysis, and proning-meeting criteria for VV-ECMO in an experienced center. Further escalation of ventilator settings or oscillatory ventilation adds risk with limited additional benefit. Low-dose vasopressor does not mandate VA-ECMO; VV-ECMO is appropriate when cardiac function is adequate and shock is not predominant.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Severe influenza A pneumonia with refractory hypoxemia; PaO2/FiO2 ratio 70–<80 despite lung-protective ventilation (TV 6 mL/kg), high PEEP (14), FiO2 0.9, paralysis, and prolonged prone positioning; hemodynamics relatively stable (MAP 72 on low-dose norepinephrine, lactate 1.8); on-site experienced ECMO team with capacity; family desires aggressive support.\\nThese findings satisfy widely accepted criteria for VV-ECMO in severe ARDS after failure of optimal conventional therapy. Thus B is the single best answer.\\nOption A: Escalating PEEP to 20 risks barotrauma/hemodynamic compromise and is not preferred over ECMO once evidence-based rescue options are exhausted. C: HFOV is no longer recommended in adult ARDS after negative trials. D: Further nitric oxide/proning is unlikely to change outcome after documented refractoriness and may delay definitive therapy. E: VA-ECMO is not indicated without significant cardiogenic shock; low-dose vasopressor alone does not justify VA configuration.\\nNo internal contradictions or underspecification; ECMO capacity is stated as present. Medical content is consistent with modern ARDS/ECMO practice (e.g., EOLIA-style criteria).\\nMinimal fix: Clarify that echocardiography shows preserved cardiac function to further justify VV- rather than VA-ECMO, though this is already strongly implied by stable hemodynamics.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Severe influenza A pneumonia with refractory hypoxemia; PaO2/FiO2 ratio 70–<80 despite lung-protective ventilation (TV 6 mL/kg), high PEEP (14), FiO2 0.9, paralysis, and prolonged prone positioning; hemodynamics relatively stable (MAP 72 on low-dose norepinephrine, lactate 1.8); on-site experienced ECMO team with capacity; family desires aggressive support.\nThese findings satisfy widely accepted criteria for VV-ECMO in severe ARDS after failure of optimal conventional therapy. Thus B is the single best answer.\nOption A: Escalating PEEP to 20 risks barotrauma/hemodynamic compromise and is not preferred over ECMO once evidence-based rescue options are exhausted. C: HFOV is no longer recommended in adult ARDS after negative trials. D: Further nitric oxide/proning is unlikely to change outcome after documented refractoriness and may delay definitive therapy. E: VA-ECMO is not indicated without significant cardiogenic shock; low-dose vasopressor alone does not justify VA configuration.\nNo internal contradictions or underspecification; ECMO capacity is stated as present. Medical content is consistent with modern ARDS/ECMO practice (e.g., EOLIA-style criteria).\nMinimal fix: Clarify that echocardiography shows preserved cardiac function to further justify VV- rather than VA-ECMO, though this is already strongly implied by stable hemodynamics.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-010", "question": "A 10-year-old boy with a history of intermittent asthma presents with 3 weeks of fever, weight loss, night sweats, and progressive joint pains. Exam: non-blanching palpable purpura on lower extremities, mononeuritis multiplex with foot drop, and hypertension (130/86 mmHg). No asthma exacerbation. Labs: ESR 90 mm/hr, CRP 12 mg/dL, creatinine 1.1 mg/dL, urinalysis with 1+ protein and few RBCs, hepatitis B surface antigen positive, high HBV DNA titer, negative ANCA. CT angiography: multiple microaneurysms in mesenteric and renal arteries. What is the most appropriate initial treatment strategy?", "options": ["High-dose corticosteroids plus cyclophosphamide without antiviral therapy", "Start entecavir and delay immunosuppression until HBV viral load is suppressed", "High-dose corticosteroids plus plasma exchange and antiviral therapy", "Rituximab with low-dose steroids and entecavir prophylaxis", "Plasma exchange and entecavir only, avoiding immunosuppression"], "answer": "C", "answer_index": 2, "explanation": "He has HBV-associated polyarteritis nodosa with medium-vessel aneurysms and high viral load. Management requires control of both vasculitis and viral replication: short-course high-dose steroids with plasma exchange and concurrent antiviral therapy is recommended. Prolonged cyclophosphamide without antivirals worsens HBV; antivirals alone are insufficient in active PAN; rituximab is less established in HBV-PAN.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Child with intermittent asthma (not currently flaring), 3 weeks of systemic symptoms (fever, weight loss, night sweats), palpable purpura, mononeuritis multiplex with foot drop, hypertension, elevated inflammatory markers, mild renal involvement, hepatitis B surface antigen positive with high HBV DNA, negative ANCA, and CT angiography showing microaneurysms in mesenteric/renal arteries. This is classic HBV-associated polyarteritis nodosa. Standard teaching: HBV-PAN is treated with a short course of high-dose glucocorticoids to control vasculitis, plus plasma exchange to remove immune complexes, combined with antiviral therapy to clear HBV.\\nOption C correctly includes all three components. A is incorrect because cyclophosphamide without antivirals risks worsening HBV; guidelines favor antivirals and often avoid prolonged cytotoxic therapy in HBV-PAN. B and E undertreat active, organ-threatening vasculitis by withholding immunosuppression. D (rituximab) is less established for HBV-PAN and omits plasma exchange. No internal contradictions or underspecification are apparent.\\nMinimal fix: Specify “short course of high-dose corticosteroids” in option C to reflect guideline emphasis on limiting steroid duration in HBV-associated PAN.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Child with intermittent asthma (not currently flaring), 3 weeks of systemic symptoms (fever, weight loss, night sweats), palpable purpura, mononeuritis multiplex with foot drop, hypertension, elevated inflammatory markers, mild renal involvement, hepatitis B surface antigen positive with high HBV DNA, negative ANCA, and CT angiography showing microaneurysms in mesenteric/renal arteries. This is classic HBV-associated polyarteritis nodosa. Standard teaching: HBV-PAN is treated with a short course of high-dose glucocorticoids to control vasculitis, plus plasma exchange to remove immune complexes, combined with antiviral therapy to clear HBV.\nOption C correctly includes all three components. A is incorrect because cyclophosphamide without antivirals risks worsening HBV; guidelines favor antivirals and often avoid prolonged cytotoxic therapy in HBV-PAN. B and E undertreat active, organ-threatening vasculitis by withholding immunosuppression. D (rituximab) is less established for HBV-PAN and omits plasma exchange. No internal contradictions or underspecification are apparent.\nMinimal fix: Specify “short course of high-dose corticosteroids” in option C to reflect guideline emphasis on limiting steroid duration in HBV-associated PAN.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]